Efficacy of Lapaquistat Acetate on Blood Cholesterol Levels in Treating Subjects With Hypercholesterolemia

PHASE3TerminatedINTERVENTIONAL
Enrollment

657

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

May 31, 2008

Study Completion Date

May 31, 2008

Conditions
Hypercholesterolemia
Interventions
DRUG

Lapaquistat acetate

Lapaquistat acetate 50 mg, tablets, orally, once daily for up to 12 weeks.

DRUG

Placebo

Lapaquistat acetate placebo-matching tablets, orally, once daily for up to 12 weeks.

Trial Locations (60)

Unknown

Tallinn

Tartu

Balatonfüred

Budapest

Debrecen

Érd

Pécs

Szekszárd

Beersheba

Hadera

Haifa

Jerusalem

Kfar Saba

Nahariya

Safed

Tel Aviv

Daugavpils

Kuldīga

Riga

Amsterdam

Breda

GA Nijmegen

Groningen

Hoorn

Rotterdam

Utrecht

Zoetermeer

Ålesund

Elverum

Hamar

Kongsberg

Oslo

Moscow

Saint Petersburg

Saratov

Tyumen

Volgograd

Bratislava

Dolný Kubín

Košice

Nitra

Nové Mesto nad Váhom

Trebišov

Córdoba

Madrid

Pontevedra

REUS (Tarragona)

Valencia

Dnipro

Kharkiv

Kiev

Kyiv

Lutsk

Lviv

Belfast

Bolton

Glasgow, Scotland

Oldham

Paignton, Devon

Sheffield

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Takeda

INDUSTRY